secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001628280-24-030403
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion monetizes European bempedoic acid royalties for $304.7M, pays off Oberland facility
--------------------------------------------------------------------------------

- Received $304.7M from OMERS in exchange for 100% of European bempedoic acid royalty until OMERS receives 1.7x investment (≈$518M), then royalties revert to Esperion.
- Used proceeds to early payoff and termination of Oberland Capital revenue interest facility for $343.75M cash, removing senior secured liens.
- Esperion retains potential future commercial milestones from DSE of up to $300M based on net sales thresholds.
- Royalty to OMERS is tiered 15-25% of DSE net sales; Esperion regains full royalty stream after cap is reached.
- CFO Ben Halladay cited enhanced balance sheet and increased operational flexibility to focus on U.S. commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024030403/0001628280-24-030403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024030403/espr-20240627.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-030403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer